The FDA lifted a clinical hold on Intellia Therapeutics’ Magnitude Phase 3 trial of nexiguran ziclumeran (nex‑z) for transthyretin amyloidosis with cardiomyopathy (ATTR‑CM), allowing enrollment to resume with added safety restrictions. Regulators will exclude patients with certain liver conditions, low ejection fraction or recent cardiovascular instability; liver enzymes will be monitored more closely and short‑term steroid guidance provided. Intellia said the agreement aligns the trial with new monitoring measures and allows the company to continue toward completion of enrollment in both Magnitude trials.